Aspergillus

NEW YORK (GenomeWeb) — Molecular testing methods such as nucleic acid sequence-based amplification (NASBA) and qPCR, administered either in combination or separately, are superior to routinely used ELISA-based assays for diagnosing invasive aspergillosis, according to a newly published retrospect

Irish clinical diagnostics company Trinity Biotech has acquired the blood bank screening and certain molecular assets of UK-based personalized medicine and clinical diagnostics firm Lab21, the companies said today.

BD Diagnostics, a segment of Becton Dickinson, and Lab 21 will develop the real-time PCR-based test as an in vitro diagnostic product.

Today's announcement is in line with BD's plans to bring new assays to the BD Max System in a "broad range" of diseases.

Gen-Probe's Prodesse ProAdeno+ assay; Myconostica's MycAssay Aspergillus test; Warnex launches Septin9 test in Canada.

Myconostica's MycAssay Aspergillus gets CE mark for serum.

The UK-based company also signed on Inverness Medical Canada to distribute its products in the country.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.